Abstract
Objective
To investigate the efficacy of integrated Chinese and Western medicine extending the progression-free survival (PFS) and overall survival (OS) of limited-stage small cell lung cancer (LS-SCLC) patients after the first-line chemoradiotherapy.
Methods
The data of 67 LS-SCLC patients who received combined treatment of CM and Western medicine (WM) between January 2013 and May 2020 at the outpatient clinic of Guang’anmen Hospital were retrospectively analyzed. Thirty-six LS-SCLC patients who received only WM treatment was used as the WM control group. The medical data of the two groups were statistically analyzed. Survival analysis was performed using the product-limit method (Kaplan—Meier analysis). The median OS and PFS were calculated, and survival curves were compared by the Log rank test. The cumulative survival rates at 1, 2, and 5 years were estimated by the life table analysis. Stratified survival analysis was performed between patients with different CM administration time.
Results
The median PFS in the CM and WM combination treatment group and the WM group were 19 months (95% CI: 12.357–25.643) vs. 9 months (95% CI: 5.957–12.043), HR=0.43 (95% CI: 0.27–0.69, P<0.001), respectively. The median OS in the CM and WM combination group and the WM group were 34 months (95% CI could not be calculated) vs. 18.63 months (95% CI: 16.425–20.835), HR=0.40 (95% CI: 0.24–0.66, P<0.001), respectively. Similar results were obtained in the further stratified analysis of whether the duration of CM administration exceeded 18 and 24 months (P<0.001).
Conclusion
The combination treatment of CM and WM with continuing oral administration of CM treatment after the first-line chemoradiotherapy for LS-SCLC patients produced better prognosis, lower risks of progression, and longer survival than the WM treatment alone. (Registration No. ChiCTR2200056616)
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
Welter S, Aigner C, Roesel C. The role of surgery in high grade neuroendocrine tumours of the lung. J Thorac Dis 2017;9:S1474–S1483.
Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol 2015;10:1133–1141.
Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist 2009;14:986–994.
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med 2017;376:2109–2121.
Kalemkerian GP, Schneider BJ. Advances in small cell lung cancer. Hematol Oncol Clin North Am 2017;31:143–156.
Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol 2007;25:4137–4145.
Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, et al. New approaches to SCLC therapy: from the laboratory to the clinic. J Thorac Oncol 2020;15:520–540.
Hu J, Wang Y, Zhang Y, Yu Y, Chen H, Liu K, et al. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential. Cancer Med 2019;8:4338–4347.
Zimmerman S, Das A, Wang S, Julian R, Gandhi L, Wolf J. 2017–2018 scientific advances in thoracic oncology: small cell lung cancer. J Thorac Oncol 2019;14:768–783.
Xu J, Qiu F. Advances of radiotherapy for limited-stage small cell lung cancer. J Chin Oncol 2019;25:398–401.
Tendler S, Grozman V, Lewensohn R, Tsakonas G, Viktorsson K, De Petris L. Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden. Lung Cancer 2018;120:75–81.
Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265–271.
Nakahara Y, Sasaki J, Fukui T, Otani S, Igawa S, Hayakawa K, et al. The role of prophylactic cranial irradiation for patients with small-cell lung cancer. JPN J Clin Oncol 2018;48:26–30.
Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6006–6011.
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, et al. National Comprehensive Cancer Network. Small cell lung cancer. J Natl Compr Canc Netw 2013;11:78–98.
Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, et al. Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer—what limits limited disease? Lung Cancer 2002;37:271–276.
Lin HS, ed. Guidelines for TCM diagnosis and treatment of malignant tumors. Beijing: People’s Medical Publishing House; 2014.
Wang XQ, Zhang Y, Hou W, Wang YT, Zheng JB, Li J, et al. Association between Chinese medicine therapy and survival outcomes in postoperative patients with NSCLC: a multicenter, prospective, cohort study. Chin J Integr Med 2019;25:812–819.
Chen H, Horita N, Ito K, Nagakura H, Hara Y, Kobayash N, et al. Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network metaanalysis. Ther Adv Med Oncol 2020;12:1758835920965841.
Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians Guideline. J Clin Oncol 2015;33:4106–4111.
Byers LA, Rudin CM. Small cell lung cancer: where do we go from here. Cancer 2015;121:664–672.
Kalemkerian GP. Small cell lung cancer. Semin Respir Crit Care Med 2016;37:783–796.
Gaspar LE, Gay EG, Crawford J, Putnam JB, Herbst RS, Bonner JA. Limited-stage small-cell lung cancer (stages I–III): observations from the National Cancer Data Base. Clin Lung Cancer 2005;6:355–360.
Shivapriya PM, Singh A, Pandey P, Chhabra N, Sahoo AK, Paital B, et al. Pathways in small cell lung cancer and its therapeutic perspectives. Front Biosci (Landmark Ed) 2021;26:1668–1678.
Wang Y, Zou S, Zhao Z, Liu P, Ke C, Xu S. New insights into small-cell lung cancer development and therapy. Cell Biol Int 2020;44:1564–1576.
He SL, Guo QJ, Xi YP, Wei HM, Hua BJ, Zhang JL. Observation of the therapeutic effect of integrative medicine onchemosensitive small cell lung cancer by HUA Bao-jin. Beijing J Tradit Chin Med (Chin) 2018;37:1107–1110,1115.
Liu R, He SL, Zhao YC, Zheng HG, Li CH, Bao YJ, et al. Chinese herbal decoction based on syndrome differentiation as maintenance therapy in patients with extensive-stage small-cell lung cancer: an exploratory and small prospective cohort study. Evid Based Complement Alternat Med 2015;2015:601067.
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883–895.
Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol 2020;15:426–435.
Acheampong E, Abed A, Morici M, Bowyer S, Amanuel B, Lin W, et al. Tumour PD-L1 expression in small-cell lung cancer: a systematic review and meta-analysis. Cells 2020;9:2393.
Feng Z, Feng Z, Han J, Cheng W, Su B, Mo J, et al. Antinociceptive effects of Shenling Baizhu through PI3K-Akt-mTOR signaling pathway in a mouse model of bone metastasis with small-cell lung cancer. Evid Based Complement Alternat Med 2020;2020:4121483.
Peng S, Dong W, Chu Q, Meng J, Yang H, Du Y, et al. Traditional Chinese medicine Brucea javanica oil enhances the efficacy of anlotinib in a mouse model of liver-metastasis of small-cell lung cancer. In Vivo 2021;35:1437–1441.
Ran WH, Huang ZS, Wang EY, Ren BN, Huang XP, Mo YB, et al. Clinical research of limited stage small cell lung cancer treated by Chinese medicine. J Chongqing Med Univ (Chin) 2010;35:1756–1758.
Author information
Authors and Affiliations
Contributions
Li CH and Hua BJ contributed to study concepts. Qi RZ and He SL contributed to study design. Li Y, Hu JQ, Zhao YW, He J and Cheng MQ contributed to data acquisition. Li CH and Geng L contributed to quality control of data and algorithms. Qi RZ, He SL and Li CH contributed to data analysis and interpretation. Li CH and Hua BJ contributed to statistical analysis. Li CH and Qi RZ contributed to manuscript preparation. Qi RZ, Li Y and Zhao YW contributed to manuscript editing. Li CH contributed to manuscript review. All authors gave the final approval for submission and publicarion of the manuscript.
Corresponding author
Additional information
Conflict of Interest
None declared.
Supported by the Science and Technology Innovation Project of the China Academy of Chinese Medical Sciences (No. CI2021A01808), the Natural Science Foundation of Beijing (No. 7212189), the Outstanding Young Scientific and Technological Talents (Innovation) Training Program of China Academy of Chinese Medical Sciences (No. ZZ15-YQ-026)
Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
Qi, Rz., He, Sl., Li, Y. et al. Retrospective Clinical Study on Integrated Chinese and Western Medicine in Treatment of Limited-Stage Small Cell Lung Cancer. Chin. J. Integr. Med. 29, 675–682 (2023). https://doi.org/10.1007/s11655-022-3682-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-022-3682-9